• About
    • Overview
    • Leadership
    • Board of Directors
  • Products
    • SYMJEPI® (epinephrine)
    • ZIMHI® (naloxone)
  • Pipeline
  • Patients
  • Investors & Media
  • Partnerships
  • Contact Us
Menu
  • About
    • Overview
    • Leadership
    • Board of Directors
  • Products
    • SYMJEPI® (epinephrine)
    • ZIMHI® (naloxone)
  • Pipeline
  • Patients
  • Investors & Media
  • Partnerships
  • Contact Us

Category: SYMJEPI Press

CBC News (7/9/19): Novartis launches rival to EpiPen for allergy emergencies in U.S.

Contemporary Clinic (7/9/19): New Epinephrine Injection Launched in Retail Pharmacies

Pharma Letter (7/9/19): Sandoz debuts US retail sales of Symjepi

Pharmacy Times (7/9/19): Launch of New Epinephrine Injection Extended to Include Retail Pharmacies

Seeking Alpha (7/9/19): Sandoz extends SYMJEPI injection launch to US pharmacies

Fox Business (7/9/19): Novartis to sell allergy shots in the U.S. amid EpiPen shortage

Reuters (7/9/19): Novartis to sell epinephrine injector in U.S. Pharmacies amid EpiPen shortage

Becker’s Hospital Review (7/9/19): Generic alternative to EpiPen released amid allergy treatment shortage

FirstWord Pharma (7/9/19): Novartis extends SYMJEPI launch to US pharmacies amid shortage of Mylan’s EpiPen

← older

Sign Up For DMK Pharmaceuticals Email Alerts

Choose Your Preferences

DMK Pharmaceuticals is a clinical stage neuro-biotechnology company focused on the development and commercialization of potential blockbuster products for the treatment of a variety of neuro-based disorders with significant unmet medical needs.

Linkedin Twitter

COMPANY

  • About Us
  • Overview
  • Leadership
  • Board of Directors

PRODUCTS

  • SYMJEPI® (epinephrine)
  • ZIMHI® (naloxone)

PIPELINE

  • New Molecular Entities

INVESTORS & MEDIA

  • Overview
  • News & Releases
  • Stock Information
  • SEC Filings
  • Events and Presentations
  • Corporate Governance
  • Email Alerts

CONNECT

  • Partnerships
  • Contact Us

© 2023 Copyright DMK Pharmaceuticals

  • Terms and Conditions
  • Privacy Policy
Adamis Pharmaceuticals logo

ADAMIS Announces Merger With DMK Pharmaceuticals

What is DMK?
Private, clinical-stage, neuro-biotech company
  • Focused on developing potential blockbuster products for underserved patients.
  • Product candidates selected and developed from proprietary library of approximately 750 small molecule neuropeptide analogues with broad utility.

Developing multiple first-in-class products targeting large unmet needs
  • Addiction
  • Acute and chronic pain
  • Parkinson’s disease
  • Bladder control
  • Other neuro-based diseases

Want to learn more?

Read our press release go to our Investor Relations page or visit https://dmkpharma.com/

Check this page for the most recent updates regarding the merger process.